Clonazepam (Psy and Mixed indications) updated on 02-10-2025

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15674
R64712
Coste (Indications other than epilepsy), 2020 Gestational age at birth (< 37 WA) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No BZD Coexposure: No (among antiseizure medications) 1.43 [1.16;1.77] C 93/1,246   91,255/1,710,441 91,348 1,246
ref
S15670
R64697
Kilic (Mixed indications), 2014 Preterm (< 37 weeks) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes BZD Coexposure: No (among antiseizure medications) 1.60 [1.00;2.40] 23/262   33,974/676,834 33,997 262
ref
Total 2 studies 1.46 [1.21;1.77] 125,345 1,508
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Indications other than epilepsy), 2020Coste, 2020 1 1.43[1.16; 1.77]91,3481,24681%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Kilic (Mixed indications), 2014Kilic, 2014 2 1.60[1.00; 2.40]33,99726219%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.46[1.21; 1.77]125,3451,5080.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Indications other than epilepsy; 2: Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.46[1.21; 1.77]125,3451,5080%NACoste (Indications other than epilepsy), 2020 Kilic (Mixed indications), 2014 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.46[1.21; 1.77]125,3451,5080%NACoste (Indications other than epilepsy), 2020 Kilic (Mixed indications), 2014 2 Tags Adjustment   - No  - No 1.43[1.16; 1.77]91,3481,246 -NACoste (Indications other than epilepsy), 2020 1   - Yes  - Yes 1.60[1.03; 2.48]33,997262 -NAKilic (Mixed indications), 2014 1 BZD Coexposure   - No (among antiseizure medications)  - No (among antiseizure medications) 1.46[1.21; 1.77]125,3451,5080%NACoste (Indications other than epilepsy), 2020 Kilic (Mixed indications), 2014 2 All studiesAll studies 1.46[1.21; 1.77]125,3451,5080%NACoste (Indications other than epilepsy), 2020 Kilic (Mixed indications), 2014 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.46[1.21; 1.77]125,3451,5080%NACoste (Indications other than epilepsy), 2020 Kilic (Mixed indications), 2014 20.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Veroniki a (NMA) (Clonazepam) (All indication ...Veroniki a (NMA) (Clonazepam) (All indications) (Preterm birth) 0.86[0.48; 1.39]NA-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 1.46[1.21; 1.77]0%1,508----Coste (Indications other than epilepsy), 2020 Kilic (Mixed indications), 2014 20.510.01.0